Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics
John J.V. McMurray, David L. DeMets, Silvio E. Inzucchi, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 11, pp. 1402-1411
Open Access | Times Cited: 188

Showing 1-25 of 188 citing articles:

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi, et al.
New England Journal of Medicine (2019) Vol. 381, Iss. 21, pp. 1995-2008
Open Access | Times Cited: 5281
Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF)
Kevin Damman, Joost C. Beusekamp, Eva M. Boorsma, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 4, pp. 713-722
Open Access | Times Cited: 368
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction
Mikhail Kosiborod, Pardeep S. Jhund, Kieran F. Docherty, et al.
Circulation (2019) Vol. 141, Iss. 2, pp. 90-99
Open Access | Times Cited: 297
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction
Pardeep S. Jhund, Scott D. Solomon, Kieran F. Docherty, et al.
Circulation (2020) Vol. 143, Iss. 4, pp. 298-309
Open Access | Times Cited: 239
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age
Felipe A. Martínez, Matteo Serenelli, José Carlos Nicolau, et al.
Circulation (2019) Vol. 141, Iss. 2, pp. 100-111
Open Access | Times Cited: 179
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
James P. Curtain, Kieran F. Docherty, Pardeep S. Jhund, et al.
European Heart Journal (2021) Vol. 42, Iss. 36, pp. 3727-3738
Open Access | Times Cited: 176
Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet–Induced Obese Mice
Xiaodong Sun, Fang Han, Qingguo Lü, et al.
Diabetes (2020) Vol. 69, Iss. 6, pp. 1292-1305
Open Access | Times Cited: 159
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction
Jawad H. Butt, Pooja Dewan, Béla Merkely, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 6, pp. 820-830
Closed Access | Times Cited: 101
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
Carly Adamson, Kieran F. Docherty, Hiddo J.L. Heerspink, et al.
Circulation (2022) Vol. 146, Iss. 6, pp. 438-449
Open Access | Times Cited: 93
Pharmacotherapy of type 2 diabetes: An update and future directions
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, et al.
Metabolism (2022) Vol. 137, pp. 155332-155332
Closed Access | Times Cited: 93
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
Matteo Serenelli, Michael Böhm, Silvio E. Inzucchi, et al.
European Heart Journal (2020) Vol. 41, Iss. 36, pp. 3402-3418
Open Access | Times Cited: 109
Effects of canagliflozin on human myocardial redox signalling: clinical implications
Hidekazu Kondo, Ioannis Akoumianakis, Ileana Badi, et al.
European Heart Journal (2021) Vol. 42, Iss. 48, pp. 4947-4960
Open Access | Times Cited: 93
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Thomas A. Zelniker, Eugene Braunwald
Journal of the American College of Cardiology (2020) Vol. 75, Iss. 4, pp. 435-447
Open Access | Times Cited: 83
Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
Justin Parizo, Jeremy D. Goldhaber‐Fiebert, Joshua A. Salomon, et al.
JAMA Cardiology (2021) Vol. 6, Iss. 8, pp. 926-926
Open Access | Times Cited: 81
Effect of dapagliflozin on anaemia in DAPA‐HF
Kieran F. Docherty, James P. Curtain, Inder S. Anand, et al.
European Journal of Heart Failure (2021) Vol. 23, Iss. 4, pp. 617-628
Open Access | Times Cited: 73
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index
Carly Adamson, Pardeep S. Jhund, Kieran F. Docherty, et al.
European Journal of Heart Failure (2021) Vol. 23, Iss. 10, pp. 1662-1672
Open Access | Times Cited: 59
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
Jawad H. Butt, Kieran F. Docherty, Pardeep S. Jhund, et al.
European Journal of Heart Failure (2021) Vol. 24, Iss. 3, pp. 513-525
Open Access | Times Cited: 59
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis
Takayoshi Kanie, Atsushi Mizuno, Yoshimitsu Takaoka, et al.
Cochrane library (2021) Vol. 2021, Iss. 10
Open Access | Times Cited: 59
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
Kirsty McDowell, Paul Welsh, Kieran F. Docherty, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 6, pp. 1066-1076
Open Access | Times Cited: 46
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes
P. Natale, David J. Tunnicliffe, Tadashi Toyama, et al.
Cochrane library (2024) Vol. 2024, Iss. 5
Closed Access | Times Cited: 9
EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction
Mingming Yang, Toru Kondo, Atefeh Talebi, et al.
JACC Heart Failure (2025) Vol. 13, Iss. 2, pp. 277-292
Open Access | Times Cited: 1
Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits
Subodh Verma
The American Journal of Cardiology (2019) Vol. 124, pp. S36-S44
Open Access | Times Cited: 74
Heart failure in the last year: progress and perspective
Daniela Tomasoni, Marianna Adamo, Markus S. Anker, et al.
ESC Heart Failure (2020) Vol. 7, Iss. 6, pp. 3505-3530
Open Access | Times Cited: 68
Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF
Muthiah Vaduganathan, Gregg C. Fonarow, Stephen J. Greene, et al.
JACC Heart Failure (2020) Vol. 8, Iss. 6, pp. 469-480
Closed Access | Times Cited: 65
Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction
Kieran F. Docherty, Pardeep S. Jhund, Inder S. Anand, et al.
Circulation (2020) Vol. 142, Iss. 17, pp. 1623-1632
Open Access | Times Cited: 65
Page 1 - Next Page

Scroll to top